Result of General Meeting and Total Voting Rights
28/03/2022 11:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220328:nRSb2432Ga&default-theme=true
RNS Number : 2432G Destiny Pharma PLC 28 March 2022
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED
HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES,
AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER
JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
Destiny Pharma plc
("Destiny" or the "Company")
Result of General Meeting
and
Total Voting Rights
Brighton, United Kingdom - 28 March 2022 - Destiny Pharma plc (AIM:DEST) a
clinical stage biotechnology company focused on the development of novel
medicines to prevent life threatening infections, announces that, at the
General Meeting held earlier today, all resolutions proposed were duly passed
by shareholders on a poll.
Accordingly, the Company has raised total gross proceeds
of approximately £6.45 million from the Fundraising and has allotted a
total of 12,909,007 New Shares. Admission of the 12,909,007 New Shares,
comprised of the Placing Shares, the Subscription Shares and the Open Offer
Shares, is expected to occur on 29 March 2022.
Following Admission on 29 March 2022, the Company's issued ordinary share
capital will comprise 73,307,105 Ordinary Shares, none of which are held in
treasury. The above figure of 73,307,0105 may be used by Shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
voting rights of the Company under the FCA's Disclosure Guidance and
Transparency Rules.
A summary of the votes received for the General Meeting will be made available
on the Company's website at www.destinypharma.com.
Unless otherwise defined herein, capitalised terms used in this announcement
shall have the same meanings as defined in the announcement of the Fundraising
made by the Company on 8 March 2022.
Enquiries:
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)
Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
MC Services AG (Joint Broker)
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Neil Clark
2. Reason for the Notification
a) Position/status Chief Executive Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code DEST GB00BDHSP575
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
50 pence 50,000
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 28 March 2022
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
Aggregated volume
Price
See 4c) above
e)
Date of the transaction
28 March 2022
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Shaun Claydon
2. Reason for the Notification
a) Position/status Chief Financial Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code DEST GB00BDHSP575
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
50 pence 10,000
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 28 March 2022
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
Aggregated volume
Price
See 4c) above
e)
Date of the transaction
28 March 2022
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Nick Rodgers
2. Reason for the Notification
a) Position/status Chairman
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code DEST GB00BDHSP575
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
50 pence 50,000
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 28 March 2022
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
Aggregated volume
Price
See 4c) above
e)
Date of the transaction
28 March 2022
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Debra Barker
2. Reason for the Notification
a) Position/status Non-Executive Director
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary shares of 1 pence each ("Ordinary Shares")
Identification code DEST GB00BDHSP575
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
50 pence 30,000
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 28 March 2022
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
Aggregated volume
Price
See 4c) above
e)
Date of the transaction
28 March 2022
f)
Place of the transaction
London Stock Exchange, AIM Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TVRZZGZFGRKGZZM